VEGF receptor‐2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis

[1]  M. Shibuya,et al.  Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Lewis,et al.  Vascular endothelial growth factor and the nervous system , 2004, Neuropathology and applied neurobiology.

[3]  L. Claesson‐Welsh,et al.  The Adaptor Protein Shb Binds to Tyrosine 1175 in Vascular Endothelial Growth Factor (VEGF) Receptor-2 and Regulates VEGF-dependent Cellular Migration* , 2004, Journal of Biological Chemistry.

[4]  D. Hicklin,et al.  Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development , 2004, Journal of Cell Science.

[5]  M. Frame,et al.  Newest findings on the oldest oncogene; how activated src does it , 2004, Journal of Cell Science.

[6]  J. Huot,et al.  Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38 , 2004, Oncogene.

[7]  Lena Claesson-Welsh,et al.  Ligand-induced Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Heterodimerization with VEGFR-2 in Primary Lymphatic Endothelial Cells Regulates Tyrosine Phosphorylation Sites* , 2003, Journal of Biological Chemistry.

[8]  L. Claesson‐Welsh,et al.  VEGF receptor signal transduction. , 2003, Science's STKE : signal transduction knowledge environment.

[9]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[10]  Napoleone Ferrara,et al.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.

[11]  D. Mukhopadhyay,et al.  KDR Stimulates Endothelial Cell Migration through Heterotrimeric G Protein Gq/11-mediated Activation of a Small GTPase RhoA* , 2002, The Journal of Biological Chemistry.

[12]  Stephen J Boyer,et al.  Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. , 2002, Current topics in medicinal chemistry.

[13]  J. Byrd,et al.  Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. , 2002, Seminars in oncology.

[14]  Lena Claesson-Welsh,et al.  VEGF Receptor Signal Transduction , 2001, Science's STKE.

[15]  D. Mukhopadhyay,et al.  Tyrosine Residues 951 and 1059 of Vascular Endothelial Growth Factor Receptor-2 (KDR) Are Essential for Vascular Permeability Factor/Vascular Endothelial Growth Factor-induced Endothelium Migration and Proliferation, Respectively* , 2001, The Journal of Biological Chemistry.

[16]  M. Shibuya,et al.  A single autophosphorylation site on KDR/Flk‐1 is essential for VEGF‐A‐dependent activation of PLC‐γ and DNA synthesis in vascular endothelial cells , 2001, The EMBO journal.

[17]  Till Acker,et al.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions , 2001, Nature Medicine.

[18]  L. Claesson‐Welsh,et al.  VEGF-induced activation of phosphoinositide 3-kinase is dependent on focal adhesion kinase. , 2001, Experimental cell research.

[19]  P. King,et al.  Cutting Edge: T Cell-Specific Adapter Protein Inhibits T Cell Activation by Modulating Lck Activity , 2000, The Journal of Immunology.

[20]  L. Mayo,et al.  VRAP Is an Adaptor Protein That Binds KDR, a Receptor for Vascular Endothelial Cell Growth Factor* , 2000, The Journal of Biological Chemistry.

[21]  J. Bluestone,et al.  Ribp, a Novel Rlk/Txk- and Itk-Binding Adaptor Protein That Regulates T Cell Activation , 1999, The Journal of experimental medicine.

[22]  Y. Yun,et al.  Lad, an adapter protein interacting with the SH2 domain of p56lck, is required for T cell activation. , 1999, Journal of immunology.

[23]  R. Hungate,et al.  Vascular Endothelial Growth Factor Receptor KDR Tyrosine Kinase Activity Is Increased by Autophosphorylation of Two Activation Loop Tyrosine Residues* , 1999, The Journal of Biological Chemistry.

[24]  B. Terman,et al.  Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization , 1999, Oncogene.

[25]  C. Wernstedt,et al.  Identification of Vascular Endothelial Growth Factor Receptor-1 Tyrosine Phosphorylation Sites and Binding of SH2 Domain-containing Molecules* , 1998, The Journal of Biological Chemistry.

[26]  H. Aasheim,et al.  Molecular Cloning of a T Cell-specific Adapter Protein (TSAd) Containing an Src Homology (SH) 2 Domain and Putative SH3 and Phosphotyrosine Binding Sites* , 1998, The Journal of Biological Chemistry.

[27]  A. Ullrich,et al.  Flk-1 expression defines a population of early embryonic hematopoietic precursors. , 1997, Development.

[28]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[29]  B. Terman,et al.  Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. , 1994, Biochemical and biophysical research communications.